Division of Pediatric Hematology-Oncology, Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, CA, United States of America.
Division of Pediatric Infectious Diseases, Department of Pediatrics, David Geffen School of Medicine at University of California, Los Angeles, CA, United States of America.
PLoS One. 2021 Nov 8;16(11):e0259703. doi: 10.1371/journal.pone.0259703. eCollection 2021.
Two mRNA vaccines (BNT162b2 and mRNA-1273) against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) are globally authorized as a two-dose regimen. Understanding the magnitude and duration of protective immune responses is vital to curbing the pandemic. We enrolled 461 high-risk health services workers at the University of California, Los Angeles (UCLA) and first responders in the Los Angeles County Fire Department (LACoFD) to assess the humoral responses in previously infected (PI) and infection naïve (NPI) individuals to mRNA-based vaccines (BNT162b2/Pfizer- BioNTech or mRNA-1273/Moderna). A chemiluminescent microparticle immunoassay was used to detect antibodies against SARS-CoV-2 Spike in vaccinees prior to (n = 21) and following each vaccine dose (n = 246 following dose 1 and n = 315 following dose 2), and at days 31-60 (n = 110) and 61-90 (n = 190) following completion of the 2-dose series. Both vaccines induced robust antibody responses in all immunocompetent individuals. Previously infected individuals achieved higher median peak titers (p = 0.002) and had a slower rate of decay (p = 0.047) than infection-naïve individuals. mRNA-1273 vaccinated infection-naïve individuals demonstrated modestly higher titers following each dose (p = 0.005 and p = 0.029, respectively) and slower rates of antibody decay (p = 0.003) than those who received BNT162b2. A subset of previously infected individuals (25%) required both doses in order to reach peak antibody titers. The biologic significance of the differences between previously infected individuals and between the mRNA-1273 and BNT162b2 vaccines remains uncertain, but may have important implications for booster strategies.
两种针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的信使 RNA(mRNA) 疫苗（BNT162b2 和 mRNA-1273）已在全球范围内被批准为两剂方案。了解保护性免疫反应的幅度和持续时间对于遏制大流行至关重要。我们招募了加利福尼亚大学洛杉矶分校 (UCLA) 的 461 名高风险卫生服务工作者和洛杉矶县消防局 (LACoFD) 的急救人员，以评估先前感染 (PI) 和无感染史 (NPI) 个体对基于 mRNA 的疫苗 (BNT162b2/Pfizer- BioNTech 或 mRNA-1273/Moderna) 的体液反应。在接种疫苗之前（n = 21）和每次接种疫苗后（第 1 剂后 n = 246，第 2 剂后 n = 315），以及在第 2 剂系列完成后第 31-60 天（n = 110）和第 61-90 天（n = 190），使用化学发光微粒子免疫测定法检测疫苗接种者针对 SARS-CoV-2 刺突的抗体。两种疫苗均在所有免疫功能正常的个体中诱导出强大的抗体反应。先前感染的个体达到了更高的中位数峰值滴度（p = 0.002），并且衰减速度较慢（p = 0.047）。与无感染史的个体相比。接受 mRNA-1273 疫苗接种的无感染史个体在每次接种后（分别为 p = 0.005 和 p = 0.029）和抗体衰减速度较慢（p = 0.003）时，均显示出稍高的滴度。那些接受 BNT162b2 疫苗的人。先前感染的个体中有一部分（25%）需要两剂才能达到峰值抗体滴度。先前感染的个体之间以及 mRNA-1273 和 BNT162b2 疫苗之间的差异的生物学意义尚不确定，但可能对加强策略有重要意义。
